HLB Therapeutics Co.,Ltd.
115450
Rank in Stocks
#18263
HLB Therapeutics Co.,Ltd. operates as a biotechnology company, focusing on the... HLB Therapeutics Co.,Ltd. operates as a biotechnology company, focusing on the creation of pharmaceutical products for both the South Korean and international markets. A significant part of its research and development initiatives includes GBT-201, a compound utilizing Thymosin beta designed to treat various eye ailments such as dry eye syndrome and neurotrophic keratopathy. Additionally, the company is advancing OKN-007 as a potential therapy for glioblastoma brain tumors. Beyond its pharmaceutical endeavors, HLB Therapeutics is also involved in the wholesale distribution of vaccines and the production of electrical and electronic components like motors, pumps, and transformers. The company, which established its roots in 2000 and is based in Seongnam, South Korea, underwent a name change in December 2021, transitioning from its former identity as G-treeBNT Co., Ltd. to its current designation.
Share Price
$2.02
Market Cap
$190.66M
Change (1 day)
7.96%
Change (1 year)
-1.16%
Country
KR
Trade HLB Therapeutics Co.,Ltd. (115450)
Category
Healthcare
Revenue for HLB Therapeutics Co.,Ltd. (115450)
Revenue in Oct 2026 TTM: 0
According to HLB Therapeutics Co.,Ltd. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for HLB Therapeutics Co.,Ltd. from 2016 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2025 | $48.26M | 29.15% |
| 2024 | $37.36M | -10.01% |
| 2023 | $41.52M | 23.56% |
| 2022 | $33.60M | -8.35% |
| 2021 | $36.66M | -7.29% |
| 2020 | $39.54M | -22.56% |
| 2019 | $51.06M | 30.46% |
| 2018 | $39.14M | 143.21% |
| 2017 | $16.09M | 9.57% |
| 2016 | $14.69M | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $12.62B | - |
US
|
|
| $2.23B | - |
US
|
|
| $15.74B | - |
AU
|
|
| $6.02B | - |
NL
|
|
| - | - |
CH
|
